Furthermore, blockade of TGFβ signalling activity with the TGFβ receptor kinase inhibitor SB431542 significantly reduces Lyn turnover and activation, and subsequently enhances imatinib-mediated CML cell death in a proteasomal-dependent manner. This evidence concerns the gene TGFB1 and chronic myelogenous leukemia, BCR-ABL1 positive.